Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of inhaled SYH9061 in adults with idiopathic pulmonary fibrosis
CTR20264052Phase 2Active
- Sponsor
- CSPC NBP Pharmaceutical
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SYH9061, nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by CSPC NBP Pharmaceutical. Started Oct 2026; status: active.
02
Drugs
SYH9061nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20264052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264052.